• Product nameAnti-BRCA1 antibody [8F7]
    See all BRCA1 primary antibodies
  • Description
    Mouse monoclonal [8F7] to BRCA1
  • SpecificityThis antibody recognizes full-length BRCA1, a 220-kDa nuclear phosphoprotein. Mutations in this tumor suppressor gene greatly increase the risk of breast cancer.
  • Tested applicationsSuitable for: IHC-P, WB, IPmore details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Fusion protein, corresponding to amino acids 341-748 of Human BRCA 1.

  • Positive control
    • breast cancer tissue



Our Abpromise guarantee covers the use of ab94 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
IHC-P Use at an assay dependent concentration. Perform heat mediated antigen retrieval before commencing with IHC staining protocol. Incubate overnight and use a biotin-streptavidin amplification kit (see Al-Mulla et al).
EMSA Use at an assay dependent concentration. PubMed: 19492866
WB Use a concentration of 1 - 10 µg/ml. Predicted molecular weight: 220 kDa.
IP Use at an assay dependent concentration.


  • FunctionE3 ubiquitin-protein ligase that specifically mediates the formation of 'Lys-6'-linked polyubiquitin chains and plays a central role in DNA repair by facilitating cellular responses to DNA damage. It is unclear whether it also mediates the formation of other types of polyubiquitin chains. The E3 ubiquitin-protein ligase activity is required for its tumor suppressor function. The BRCA1-BARD1 heterodimer coordinates a diverse range of cellular pathways such as DNA damage repair, ubiquitination and transcriptional regulation to maintain genomic stability. Regulates centrosomal microtubule nucleation. Required for normal cell cycle progression from G2 to mitosis. Required for appropriate cell cycle arrests after ionizing irradiation in both the S-phase and the G2 phase of the cell cycle. Involved in transcriptional regulation of P21 in response to DNA damage. Required for FANCD2 targeting to sites of DNA damage. May function as a transcriptional regulator. Inhibits lipid synthesis by binding to inactive phosphorylated ACACA and preventing its dephosphorylation. Contributes to homologous recombination repair (HRR) via its direct interaction with PALB2, fine-tunes recombinational repair partly through its modulatory role in the PALB2-dependent loading of BRCA2-RAD51 repair machinery at DNA breaks.
  • Tissue specificityIsoform 1 and isoform 3 are widely expressed. Isoform 3 is reduced or absent in several breast and ovarian cancer cell lines.
  • PathwayProtein modification; protein ubiquitination.
  • Involvement in diseaseDefects in BRCA1 are a cause of susceptibility to breast cancer (BC) [MIM:114480]. A common malignancy originating from breast epithelial tissue. Breast neoplasms can be distinguished by their histologic pattern. Invasive ductal carcinoma is by far the most common type. Breast cancer is etiologically and genetically heterogeneous. Important genetic factors have been indicated by familial occurrence and bilateral involvement. Mutations at more than one locus can be involved in different families or even in the same case. Note=Mutations in BRCA1 are thought to be responsible for 45% of inherited breast cancer. Moreover, BRCA1 carriers have a 4-fold increased risk of colon cancer, whereas male carriers face a 3-fold increased risk of prostate cancer. Cells lacking BRCA1 show defects in DNA repair by homologous recombination.
    Defects in BRCA1 are a cause of susceptibility to breast-ovarian cancer familial type 1 (BROVCA1) [MIM:604370]. A condition associated with familial predisposition to cancer of the breast and ovaries. Characteristic features in affected families are an early age of onset of breast cancer (often before age 50), increased chance of bilateral cancers (cancer that develop in both breasts, or both ovaries, independently), frequent occurrence of breast cancer among men, increased incidence of tumors of other specific organs, such as the prostate. Note=Mutations in BRCA1 are thought to be responsible for more than 80% of inherited breast-ovarian cancer.
    Defects in BRCA1 are a cause of genetic susceptibility to ovarian cancer [MIM:113705].
  • Sequence similaritiesContains 2 BRCT domains.
    Contains 1 RING-type zinc finger.
  • DomainThe BRCT domains recognize and bind phosphorylated pSXXF motif on proteins. The interaction with the phosphorylated pSXXF motif of FAM175A/Abraxas, recruits BRCA1 at DNA damage sites.
    The RING-type zinc finger domain interacts with BAP1.
  • Post-translational
    Phosphorylation at Ser-308 by STK6/AURKA is required for normal cell cycle progression from G2 to mitosis. Phosphorylated in response to IR, UV, and various stimuli that cause checkpoint activation, probably by ATM or ATR.
    Autoubiquitinated, undergoes 'Lys-6'-linked polyubiquitination. 'Lys-6'-linked polyubiquitination does not promote degradation.
  • Cellular localizationCytoplasm; Nucleus. Localizes at sites of DNA damage at double-strand breaks (DSBs) and recruitment to DNA damage sites is mediated by the BRCA1-A complex.
  • Information by UniProt
  • Database links
  • Alternative names
    • BRCA 1 antibody
    • BRCA1 antibody
    • BRCA1/BRCA2 containing complex subunit 1 antibody
    • BRCA1/BRCA2-containing complex, subunit 1 antibody
    • BRCA1_HUMAN antibody
    • BRCAI antibody
    • BRCC 1 antibody
    • BRCC1 antibody
    • Breast and ovarian cancer susceptibility protein 1 antibody
    • Breast Cancer 1 antibody
    • Breast Cancer 1 Early Onset antibody
    • Breast cancer type 1 susceptibility protein antibody
    • BROVCA1 antibody
    • IRIS antibody
    • PNCA4 antibody
    • PPP1R53 antibody
    • Protein phosphatase 1 regulatory subunit 53 antibody
    • PSCP antibody
    • RING finger protein 53 antibody
    • RNF53 antibody
    see all

Anti-BRCA1 antibody [8F7] images

  • IHC image of ab94 staining in human breast carcinoma formalin fixed paraffin embedded tissue section, performed on a Leica BondTM system using the standard protocol F. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH6, epitope retrieval solution 1) for 20 mins. The section was then incubated with ab94, 5µg/ml, for 15 mins at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.

    For other IHC staining systems (automated and non-automated) customers should optimize variable parameters such as antigen retrieval conditions, primary antibody concentration and antibody incubation times.

References for Anti-BRCA1 antibody [8F7] (ab94)

This product has been referenced in:
  • Brázda V  et al. The central region of BRCA1 binds preferentially to supercoiled DNA. J Biomol Struct Dyn 27:97-104 (2009). Human . Read more (PubMed: 19492866) »
  • Al-Mulla F  et al. BRCA1 gene expression in breast cancer: a correlative study between real-time RT-PCR and immunohistochemistry. J Histochem Cytochem 53:621-9 (2005). Read more (PubMed: 15872055) »

See all 4 Publications for this product

Product Wall

Abcam guarantees this product to work in the species/application used in this Abreview.
Application Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)
Sample Human Tissue sections (breast)
Specification breast
Fixative Formaldehyde
Antigen retrieval step Heat mediated - Buffer/Enzyme Used: Citrated Buffer, pH6
Blocking step (agent) for 25 minute(s) · Concentration: 3% · Temperature: 25°C

Abcam user community

Verified customer

Submitted Mar 19 2012